<DOC>
	<DOCNO>NCT00054600</DOCNO>
	<brief_summary>The purpose study determine whether Extracorporeal Photopheresis UVADEX ( ECP ) prior bone marrow peripheral blood stem cell transplantation effective prevention Graft-versus-Host Disease ( GvHD ) .</brief_summary>
	<brief_title>Safety Efficacy Study Photopheresis With UVADEX Prevent Graft-versus-Host Disease</brief_title>
	<detailed_description>Approximately 30 % HLA-identical related bone marrow graft recipient 90 % patient receive bone marrow unrelated donor develop significant acute GvHD despite use prophylactic therapy cyclosporine methotrexate . About half patient respond initial treatment steroid require treatment . The remainder patient either unresponsive initial therapy become steroid-resistant time . The prognosis case poor mortality patient steroid-resistant GvHD may high 50 % . ECP technique peripheral white blood cell expose photoactivatable compound ( UVADEX ) administer extracorporeally ultraviolet A light . After cell reinfused patient , function alter , thereby activate mechanism allow regulation specific lymphocyte population . ECP show activity several inflammatory autoimmune disease , include scleroderma , rheumatoid arthritis , transplantation rejection , acute chronic GvHD . In previous single-center , open label , single-arm study 56 patient receive ECP treatment two consecutive day reduced-intensity bone-marrow conditioning prior bone marrow transplantation match partially match human donor , incidence grade II-IV acute GvHD le 10 % . This contrast expect incidence approximately 40 % . The purpose study determine role ECP , administer pre-transplant , prevent GvHD use conjunction standard myeloablative conditioning regimen .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methoxsalen</mesh_term>
	<criteria>Patients diagnosis malignancy blood ( e.g . leukemia ) allogeneic bone marrow peripheral blood stem cell transplantation treatment option . Patients candidate standard allogenic bone marrow transplant PBSC transplant . Patients must adequate renal , hepatic , pulmonary cardiac function enable patient tolerate shift volume body fluid associate extracorporeal photopheresis , determine physician 's clinical judgement . Patients must weigh least 40 kg ( 88 lb ) Patients receive prior bone marrow transplant peripheral blood stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Extracorporeal Photopheresis</keyword>
	<keyword>Graft-versus-Host Disease</keyword>
</DOC>